reports
Notification de participation par BNP Paribas Asset Management
Notification de participation par BNP Paribas Asset Management Communiqué de presse Information réglementée Bruxelles, le 18 mars 2025 - 18h CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), BNP Paribas Asset Management Holding a envoyé récemment à Solvay la notification de transparence suivante indiquant avoir franchi le seuil de 3%. Voici un résumé de la notification: Date à laquelle le seuil a été franchi Droits de vote a...
Participatiemelding van BNP Paribas Asset Management
Participatiemelding van BNP Paribas Asset Management Persbericht Gereglementeerde informatie Brussel, 18 maart 2025 - 18u CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft BNP Paribas Asset Management Holding onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de beweging: Datum van drempeloverschrijding Stemrechten na de transactie A...
Participation notification by BNP Paribas Asset Management
Participation notification by BNP Paribas Asset Management Press release Regulated information Brussels, March 18, 2025, 18:00 CET In line with Belgian transparency legislation (Law of May 2, 2007), BNP Paribas Asset Management Holding recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%. Here is a summary of the notification: Date on which the threshold was crossed Voting rights after the transaction Equivalent finan...
- Jacob Mekhael
Sequana Medical FIRST LOOK: Additional funding extends runway to YE25
Sequana announced that it has secured additional financing including a €4m convertible, and a facility agreement with GEM up to €20m, as well as amending the terms of the Kreos and PMV loans. The new cash provides funding to YE25, and gives the company breathing room to progress towards US commercialisation of the alfapump expected in 3Q25. We plan to incorporate this new financing in a future model update. BUY reiterated.
- Jacob Mekhael
- Wim Hoste
- Wim Hoste
Solvay From gold to silver in soda ash
Solvay has lost its top spot in the global soda ash market following the acquisition of Genesis Alkali by WE Soda. Whilst soda ash prices continue to be impacted in 2025 by weak end markets, we still see a case for a gradual market tightening and increasing pricing power in the years ahead. Combined with continued savings deliveries, this translates into an adjusted EBITDA CAGR forecast of 5.5% for the period 2026-2028, after a presumed flat 2025. Solvay is a base chemicals group with a prudent ...
Solvay: acquisition of own shares
Solvay: acquisition of own shares Press release - Regulated information Brussels, March 13, 2025, 6:00pm CEST In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code of Companies and Associations, Solvay SA hereby confirms that, as announced on March 6, 2025, the Company recently acquired a total of 175,300 shares of the Company on Euronext Brussels, for the purpose of meeting any delivery obligations of Solvay shares arising from grants of its 2025 long-term incentive plans. Date of repurchase Number of shares Average pric...
Solvay: acquisition d’actions propres
Solvay: acquisition d’actions propres Communiqué de presse - Information réglementée Bruxelles, le 13 mars 2025 - 18h00 CEST Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 exécutant le Code belge des sociétés et des associations, Solvay SA confirme que, comme annoncé le 6 mars 2025, la Société a récemment acquis un total de 175 300 actions de la Société sur Euronext Brussels, dans le but de répondre à toute obligation de livraison d'actions Solvay découlant de l'octroi de ses plans d'intéressement à long terme 2025. Date d’achat Nombre d’actions Prix moyen pay...
Solvay: verwerving van eigen aandelen
Solvay: verwerving van eigen aandelen Persbericht - Gereglementeerde informatie Brussel, 13 maart 2025 - 18u00 CEST In overeenstemming met artikel 8:4 van het Koninklijk Besluit van 29 april 2019 tot uitvoering van het Belgisch Wetboek van Vennootschappen en Verenigingen, maakt Solvay NV hierbij bekend dat de Vennootschap, zoals aangekondigd op 6 maart 2025, recentelijk in totaal 175 300 aandelen van de Vennootschap heeft verworven op Euronext Brussel, met de bedoeling te voldoen aan de eventuele leveringsverplichtingen van Solvay-aandelen die voortvloeien uit de toekenning van zijn...
- Stefano Toffano
- Ahmed Ben Salem
- Baptiste Lebacq
SCHP SECHE ENVIRONNEMENT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SCR SCOR SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
EKI EKINOPS SA
MTU MANITOU BF SA
GLO GL EVENTS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
BON BONDUELLE SCA
SOLB SOLVAY SA
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
ELIS ELIS SA
TUB TUBACEX S.A.
NDA AURUBIS AG
PAL PALFINGER AG
CIE CIE AUTOMOTIVE S.A.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CPINV CARE PROPERTY INVEST SA
WAF SILTRONIC AG
ZAG ZUMTOBEL GROUP AG
ALR ALIOR BANK SA
SPIE SPIE SA
RACE FERRARI NV
COPN COSMO PHARMACEUTICALS NV
RIO RIO TINTO PLC
MAU ETABLISSEMENTS MAUREL & PROM SA
BHP BHP GROUP LTD
DUE DURR AG
PIRC PIRELLI & C. S.P.A.
AMAG AMAG AUSTRIA METALL AG
GEST GESTAMP AUTOMOCION S.A.
FQT FREQUENTIS AG WIENER
GRP GREENCOAT RENEWABLES
COP COMPUGROUP MEDICAL SE & CO. KGAA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FUR FUGRO NV
EAPI EUROAPI
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
AF AIR FRANCE - KLM
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
HAVAS HAVAS N.V
- Ahmed Ben Salem
- Baptiste Lebacq
SCHP SECHE ENVIRONNEMENT
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SCR SCOR SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
EKI EKINOPS SA
MTU MANITOU BF SA
GLO GL EVENTS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
FR VALEO SE
BON BONDUELLE SCA
SOLB SOLVAY SA
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
ELIS ELIS SA
TUB TUBACEX S.A.
NDA AURUBIS AG
PAL PALFINGER AG
CIE CIE AUTOMOTIVE S.A.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CPINV CARE PROPERTY INVEST SA
WAF SILTRONIC AG
ZAG ZUMTOBEL GROUP AG
ALR ALIOR BANK SA
SPIE SPIE SA
RACE FERRARI NV
COPN COSMO PHARMACEUTICALS NV
RIO RIO TINTO PLC
MAU ETABLISSEMENTS MAUREL & PROM SA
BHP BHP GROUP LTD
DUE DURR AG
PIRC PIRELLI & C. S.P.A.
AMAG AMAG AUSTRIA METALL AG
GEST GESTAMP AUTOMOCION S.A.
FQT FREQUENTIS AG WIENER
GRP GREENCOAT RENEWABLES
COP COMPUGROUP MEDICAL SE & CO. KGAA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FUR FUGRO NV
EAPI EUROAPI
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
AF AIR FRANCE - KLM
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
HAVAS HAVAS N.V
- ING Helpdesk
Benelux Morning Notes
Air France-KLM: Surprising 4Q to the upside. CMB.TECH: A golden step into Golden Ocean? EVS: Evertz 3Q25 results. GBL: Boosting its liquidity profile. Gimv: Continued transaction spree post capital increase. Solvay: 4Q24 beat, 2025F guide in-line, reaffirmed 2028F target. Talabat: Completes InstaShop acquisition
- Guy Sips
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Solvay FIRST LOOK: Solid 4Q24, good savings delivery, broad FY25 guida...
Solvay reported better than expected 4Q underlying EBITDA, up 2% organically to 256m, which was 9% better than our forecast and 8% above CSS. Solvay remains prudent on the outlook, guiding for a broad €1.0-1.1bn range, with both KBCS and CSS currently around the midpoint. Solvay is a base chemicals group with leading market and technology positions in the vast majority of its businesses. The company favours dividends over aggressive growth (c. 8% dividend yield) and operates with a solid balance...
Solvay fourth quarter and full year 2024 results
Solvay fourth quarter and full year 2024 results Press release Regulated information Solid EBITDA and free cash flow supported by cost savings acceleration Brussels, March 6, 2025, 7.00am CET Highlights “Essential for Generations”: Solvay’s ambition is to be a leader in Essential Chemistry. Despite challenging market conditions in 2024, we proved the resilience of our business and our strong execution, delivering solid results. This allows us to confirm our 2028 EBITDA mid-single digit annual growth target. Launch of the “For Generations” roadmap, defining the foundations of Sustai...
Solvay : résultats du quatrième trimestre et de l’année 2024
Solvay : résultats du quatrième trimestre et de l’année 2024 Communiqué de presse Information réglementée EBITDA et free cash flow solides, soutenus par l'accélération des réductions de coûts Bruxelles, le 6 mars 2025 - 7h00 CET Faits marquants “Essential for Generations” : L'ambition de Solvay est d'être un leader dans la chimie essentielle. Malgré des conditions de marché difficiles en 2024, nous avons prouvé la résilience de nos activités et notre forte capacité d’exécution, en obtenant de solides résultats. Cela nous permet de confirmer notre objectif de croissance annuelle de...
Solvay 2024 vierde kwartaal en jaarresultaten
Solvay 2024 vierde kwartaal en jaarresultaten Persbericht Gereglementeerde informatie Solide EBITDA en vrije kasstroom ondersteund door versnelde kostenbesparingen Brussel, 6 maart 2025, 7u00 CET Hoogtepunten Essential for Generations: Solvay heeft de ambitie een leider te zijn in essentiële chemie. Ondanks uitdagende marktomstandigheden in 2024 hebben we de veerkracht van ons bedrijf en onze sterke uitvoering bewezen, met solide resultaten. Hierdoor kunnen we onze EBITDA-doelstelling voor 2028 bevestigen, met een ‘mid-single digit’ jaarlijkse groei.Lancering van de “For Generat...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
Sequana Medical Becoming a commercial stage medtech
With the alfapump FDA approval in liver ascites obtained in 4Q24, Sequana enters 2025 with the clear aim of building out its commercial organisation in the US. While the company's cash runway is until 1Q25, we believe the FDA approval could attract new investors into the stock, and US commercialisation is targeted for 2H25. We re-model Sequana taking into account the updated timelines, and estimate peak sales of approx. €240m for the alfapump in liver ascites in the US. This brings us to a new T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.